COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria.

丹麦哥本哈根，2024年1月31日（环球通讯社）--Ascendis Pharma A/S（纳斯达克：ASND）今天宣布，YORVIPATH®（palopegteriparatide，开发为TransCon PTH），一种甲状旁腺激素（PTH）替代疗法，用于治疗成人慢性甲状旁腺功能减退症，现已在德国和奥地利上市。

YORVIPATH is the second product developed with Ascendis Pharma’s TransCon technology platform to be launched commercially. “We are pleased to initiate the launch of YORVIPATH to address the needs expressed within the hypoparathyroidism community for a new PTH-based treatment option,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer.

YORVIPATH是Ascendis Pharma TransCon技术平台开发的第二款商业化产品。Ascendis Pharma总裁兼首席执行官扬·米克尔森（JanMikkelsen）表示：“我们很高兴启动YORVIPATH，以满足甲状旁腺功能减退症社区对新的PTH治疗方案的需求。”。

“In addition to addressing a significant unmet medical need, this launch of our second TransCon product represents a key milestone in our goal to launch the three Endocrinology Rare Disease products for which, under Vision 3x3 we target achieving regulatory approvals by 2025 and for each of which, under Vision 2030, we aim to achieve blockbuster status by 2030.

“除了解决严重未满足的医疗需求外，我们第二款TransCon产品的推出是我们推出三种内分泌罕见病产品目标的一个关键里程碑，根据愿景3x3，我们的目标是在2025年之前获得监管部门的批准，而根据愿景2030，我们的目标是在2030年之前取得轰动地位。

With an increasingly broad commercial infrastructure in place, we are well positioned to accomplish this by expanding the availability of YORVIPATH and our other approved products to meet the needs of physicians and patients around the world.” About YORVIPATH YORVIPATH (palopegteriparatide, developed as TransCon PTH) is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range across the 24-hour dosing period.

随着越来越广泛的商业基础设施的建立，我们有能力通过扩大YORVIPATH和其他经批准的产品的可用性来满足世界各地医生和患者的需求，从而实现这一目标。”关于YORVIPATH YORVIPATH（palopegteriparatide，开发为TransCon PTH）是甲状旁腺激素（PTH 1-34）的前药，每天服用一次，旨在在24小时给药期间提供正常生理范围内的甲状旁腺激素水平。

YORVIPATH was granted marketing authorization by the European Commission (EC) in November 2023 as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. A decision on YORVIPATH in the Unit.

YORVIPATH于2023年11月获得欧盟委员会（EC）的上市许可，作为PTH替代疗法，用于治疗成人慢性甲状旁腺功能减退症。关于该部队YORVIPATH的决定。